Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of polypeptides to preparation of medicament for treating or preventing rheumatoid arthritis

A rheumatoid and arthritis technology, applied in the field of polypeptides for the treatment or prevention of rheumatoid arthritis, can solve problems such as not taking too long, failing to improve the condition, and undisclosed treatment effects of other diseases, and achieve significant rheumatoid arthritis inflammation, significant social value and market value, and the effect of treating rheumatoid arthritis

Inactive Publication Date: 2012-06-20
CHINA PHARM UNIV
View PDF4 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

2. Steroid hormones. Hormones are very good analgesic and anti-inflammatory drugs, but long-term use alone cannot improve the condition, but bring many side effects. Steroids can be used as a transitional second-line slow-acting drug before it takes effect, but the dosage should be limited. small, not too long
Although the previous patent ZL200510040378.5 discloses that the sequence has a therapeutic effect on melanoma, it does not disclose the therapeutic effect on other diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptides to preparation of medicament for treating or preventing rheumatoid arthritis
  • Application of polypeptides to preparation of medicament for treating or preventing rheumatoid arthritis
  • Application of polypeptides to preparation of medicament for treating or preventing rheumatoid arthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Polypeptide I, polypeptide II and polypeptide III were all synthesized by solid phase synthesis, purified by high performance liquid chromatography, and the purity of the polypeptide was determined by RP-HPLC. The synthesis method refers to patents 201110194918.0 and 201110370529.9.

[0048] Results: The purity identification results of the synthesized polypeptides were analyzed by reverse liquid chromatography as follows: the purity of polypeptide I, polypeptide II and polypeptide III were 96.94%, 99.30%, and 96.34%, respectively, and the purity was greater than 95%, meeting the design requirements.

Embodiment 2

[0050] Immunoprotective Effect of Polypeptide I on Collagen-Induced Mouse Arthritis Animal Model

[0051] A collagen-type mouse arthritis animal model was constructed to study the therapeutic effect of polypeptide on collagen-induced arthritis (CIA) in mice. Mice were used as experimental animals, and 90 SPF grade DBA / 1 mice (provided by Sino-British SIPPR Lab.Animal Ltd), animal production license number: SCXK (Shanghai )2008-0016), male, 7-8 weeks old, with a body weight of 18-22g, were randomly divided into 9 groups, which were normal control group, model control group, 3 low, middle and high dosage groups of polypeptide I (0.2, 0.4, 0.8mg / kg) and positive drug control group (methotrexate 1mg / kg). Except the normal group, mice CIA models were established in each experimental group on day 0 by dissolving chicken cartilage type II collagen (cII) with 0.1 mol / l acetic acid into a 4 mg / ml solution and overnight in a refrigerator at 4°C. On the day of the experiment, fully em...

Embodiment 3

[0066] Protective Effect of Polypeptide I on In Vivo Immunoprotective Effect of Adjuvanted Rat Arthritis Animal Model

[0067] An animal model of adjuvant arthritis in rats was constructed to study the therapeutic effect of the polypeptide on adjuvant arthritis (AA) rats. Rats were used as experimental animals, 90 SPF grade SD rats (provided by Sino-British SIPPR Lab.Animal Ltd), animal production license number: SCXK (Shanghai) 2008 -0016), male, with a body weight of 140g-160g, were randomly divided into 9 groups, which were normal control group, model control group, 3 low, middle and high dose groups of polypeptide I (0.1, 0.2, 0.4mg / kg) and positive drug control group (Methotrexate 1mg / kg). In addition to the normal group, on the 0th day, each experimental group established a rat AA model by injecting complete Freund's adjuvant containing inactivated Mycobacterium tuberculosis (H37RA, 10mg / ml) in the left rear of the rat. 0.08ml caused rat adjuvant arthritis model. Subc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of medicament and particularly relates to polypeptides with integrin affinity and binding capacity. The polypeptides comprise a polypeptide I, a polypeptide II and a polypeptide III which can be used for preventing or treating rheumatoid arthritis; the polypeptide I has the following amino acid sequence: Ala-Cys-Asp-Cys-Arg-Gly-Asp-Cys-Phe-Cys-Gly-Gly-Gly-Gly-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, wherein the amino acid sequence comprises two pairs of disulfide bonds, and the disulfide bonds have the pairing mode of 1-4 and 2-3; the polypeptide II has the following amino acid sequence: Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp; and the polypeptide III has the following amino acid sequence: mPEG-SC20k-Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro-Gly-Gly-Gly-Gly-Arg-Gly-Asp. The polypeptides can be used for treating the rheumatoid arthritis.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a polypeptide for treating or preventing rheumatoid arthritis. Background technique [0002] Rheumatoid arthritis (RA) is the most common clinical inflammatory joint disease and one of the main disabling factors. It is about 0.5%-1.0% in the world, and the incidence of RA is about 0.4% in our country. RA can occur at any age, and the incidence rate increases with age. The high-incidence age for women is 45-55 years old, and gender is closely related to the incidence of RA, with a male-to-female ratio of about 1:3. RA is a chronic systemic inflammatory disease of unknown etiology, with chronic, symmetrical, polysynovial arthritis and extra-articular lesions as the main clinical manifestations, and belongs to autoimmune inflammatory disease. Patients often have hand or wrist pain and swelling (especially the swelling on the back of the wrist) as the first symptom, and the symptoms contin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/16A61K47/48A61P19/02A61P29/00A61K38/10
CPCA61K47/48A61K38/16A61K38/10A61P19/02A61P29/00A61K47/50C07K7/08C07K14/00
Inventor 徐寒梅浦春艳沈鸿
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products